PMV Pharmaceuticals, Inc.

NasdaqGS:PMVP Stock Report

Market Cap: US$69.9m

PMV Pharmaceuticals Management

Management criteria checks 3/4

PMV Pharmaceuticals' CEO is David Mack, appointed in Jul 2013, has a tenure of 12.83 years. total yearly compensation is $1.67M, comprised of 37.7% salary and 62.3% bonuses, including company stock and options. directly owns 2.11% of the company’s shares, worth $1.48M. The average tenure of the management team and the board of directors is 5.2 years and 5.3 years respectively.

Key information

David Mack

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage37.74%
CEO tenure12.8yrs
CEO ownership2.1%
Management average tenure5.2yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Analysis Article • May 19

PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 28

Will PMV Pharmaceuticals (NASDAQ:PMVP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jun 11

Will PMV Pharmaceuticals (NASDAQ:PMVP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 04

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 20

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 22

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Sep 08

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 10

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 11

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 22

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 09

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

PMV Pharmaceuticals press release (NASDAQ:PMVP): Q2 GAAP EPS of -$0.38 beats by $0.04. cash equivalents, and marketable securities of $277.4m
Seeking Alpha • Jul 18

PMV Pharma joins Merck to study lead candidate with Keytruda

Cancer-focused biotech PMV Pharmaceuticals (NASDAQ:PMVP) announced an agreement with Merck (MRK) on Monday to study its lead product candidate PC14586 in combination with Merck’s (MRK) anti-PD-1 therapy Keytruda in advanced solid tumors. Accordingly, PMV (PMVP) will add a combination arm to study the experimental drug in the company’s ongoing Phase 1/2 PYNNACLE trial for patients with advanced solid tumors. The combination arm, designed to assess PC14586/ Keytruda combo in patients with advanced solid tumors harboring a p53 Y220C mutation, is expected to recruit about 36 subjects. Per the terms, PMV Pharma (PMVP) will sponsor the study, and Merck (MRK) will supply Keytruda. PC14586 is an investigational small molecule designed to selectively target the p53 Y220C mutation of cancers. Read: PMV (PMVP) traded lower last month after the company announced early data from the PYNNACLE trial for PC14586.
Analysis Article • Jun 09

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 23

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 05

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jul 23

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Apr 09

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Dec 25

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

Every investor in PMV Pharmaceuticals, Inc. ( NASDAQ:PMVP ) should be aware of the most powerful shareholder groups...

CEO Compensation Analysis

How has David Mack's remuneration changed compared to PMV Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$78m

Dec 31 2025US$2mUS$628k

-US$78m

Sep 30 2025n/an/a

-US$83m

Jun 30 2025n/an/a

-US$81m

Mar 31 2025n/an/a

-US$61m

Dec 31 2024US$5mUS$607k

-US$59m

Sep 30 2024n/an/a

-US$51m

Jun 30 2024n/an/a

-US$49m

Mar 31 2024n/an/a

-US$65m

Dec 31 2023US$2mUS$586k

-US$69m

Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$74m

Dec 31 2022US$4mUS$564k

-US$73m

Sep 30 2022n/an/a

-US$72m

Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$4mUS$545k

-US$58m

Sep 30 2021n/an/a

-US$50m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$1mUS$495k

-US$34m

Sep 30 2020n/an/a

-US$31m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$628kUS$461k

-US$25m

Compensation vs Market: David's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD647.34K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Mack (63 yo)

12.8yrs
Tenure
US$1,665,191
Compensation

Dr. David H. Mack, Ph D., Co-founded PMV Pharmaceuticals, Inc. in 2013 and also serves as its President and Chief Executive Officer since July 2013. Dr. Mack joined the PMV Pharmaceuticals, Inc. in 2013.D...

Leadership Team

NamePositionTenureCompensationOwnership
David Mack
Co-Founder12.8yrsUS$1.67m2.11%
$ 1.5m
Arnold Levine
Co-Founder13.3yrsUS$161.69k0.77%
$ 536.9k
Robert Ticktin
General Counsel5.8yrsUS$861.21k0.19%
$ 129.3k
Deepika Jalota
Chief Development Officer6.9yrsUS$935.19k0.17%
$ 117.8k
Michael Carulli
Chief Financial Officer2.3yrsUS$1.38m0.14%
$ 96.7k
Tim Smith
Senior VP and Head of Corporate Development & Investor Relations4.7yrsno datano data
Crystal Zuckerman
Vice President of Human Resources3.3yrsno datano data
Binh Vu
Senior Vice President of Drug Discovery & CMCno datano datano data
Marc Fellous
Senior VP and Head of Clinical Development & Medical Affairs3yrsno datano data
Laura De Leon
VP & Head of Clinical Development Operationsno datano datano data
5.2yrs
Average Tenure
63yo
Average Age

Experienced Management: PMVP's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Mack
Co-Founder12.9yrsUS$1.67m2.11%
$ 1.5m
Arnold Levine
Co-Founder12.9yrsUS$161.69k0.77%
$ 536.9k
Charles Sawyers
Member of Clinical Advisory Boardno datano datano data
Carol Gallagher
Independent Director3.5yrsUS$65.69k0%
$ 0
Richard Heyman
Independent Chairman of the Board of Directors & Member of Scientific Advisory Board5.9yrsUS$118.19k0%
$ 0
Scott Lowe
Chairman of Scientific Advisory Board2.3yrsno datano data
Charles Baum
Independent Director & Chair of Clinical Advisory Board5.1yrsUS$174.69k0%
$ 0
Laurie Stelzer
Independent Director5.8yrsUS$81.69k0%
$ 0
Kirsten Flowers
Independent Director4.3yrsUS$69.19k0%
$ 0
Guillermina Lozano
Member of Scientific Advisory Board5.3yrsno datano data
5.3yrs
Average Tenure
64.5yo
Average Age

Experienced Board: PMVP's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 04:04
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PMV Pharmaceuticals, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Gum-Ming LoweCraig-Hallum Capital Group LLC
Joshua SchimmerEvercore ISI